NeurAxis Publishes Impressive Financial Results
NeurAxis, Inc. (NYSE: NRXS), a pioneering medical technology company focused on developing neuromodulation therapies, has announced remarkable financial results for the third quarter of 2025. The announcement highlights a significant 22% growth in revenues compared to the same period last year, cementing NeurAxis's position in the evolving healthcare landscape.
Financial Highlights for the Third Quarter of 2025
For Q3 2025, NeurAxis reported revenues totaling $811 thousand, a notable increase from $667 thousand in Q3 2024. This growth is driven by an uptick in patient enrollment and increased product awareness. However, the company faced a 27% increase in operating losses year-over-year due to heightened sales and marketing efforts, which are crucial for capturing market share.
Cash Position and Future Plans
As of September 30, 2025, NeurAxis maintains a cash balance of $4.4 million. Following this, the company successfully raised an additional $2.8 million through an at-the-market equity offering and warrant exercises in October, significantly bolstering its liquidity and paving the way for future investments.
Operational Milestones Achieved
Throughout this quarter, NeurAxis marked several significant operational achievements that elevate its standing in the medical technology field:
- Awarded its first FDA clearance aimed at treating pain associated with Functional Dyspepsia (FD) alongside nausea symptoms in adult patients.
- The company received crucial recommendations from academic society guidelines for the treatment of Functional Abdominal Pain (FAP) in patients with Irritable Bowel Syndrome (IBS) using its unique Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which is now the only FDA-cleared treatment recommended in pediatric guidelines.
- Expanded the inclusion criteria for its IB-Stim device to children aged 8 to 21 years, effectively broadening its market reach.
Expansion in Covered Lives
NeurAxis has optimized its coverage, now reaching approximately 55 million lives. This milestone is expected to facilitate larger-scale insurance coverage opportunities for its IB-Stim treatment, thereby enhancing patient access.
Insights from Management
Brian Carrico, the Chief Executive Officer of NeurAxis, expressed optimism regarding the company's trajectory. He stated, "We are preparing for a significant scaling phase in 2026, with our recent achievements setting the groundwork for larger insurance coverage. The imminent effectiveness of the CPT Category I code on January 1, 2026, positions us well for substantial revenue growth in the years ahead, supported by robust operational momentum. Our revenue in the second quarter alone increased by 22%, alongside a 38% rise in units sold due to our financial assistance programs, which provide critical support to uninsured patients."
Financial Overview for the Third Quarter
Regarding the broader financial landscape, NeurAxis reported operating expenses of $2.8 million for Q3 2025, marking a 25% increase compared to the same period in 2024. Despite the increased sales, the company experienced a net loss attributable to shareholders of $2.1 million, up from $1.8 million in Q3 2024.
Market Positioning and Future Prospects
NeurAxis's innovative approach in addressing prevalent and chronic medical conditions positions it favorably in the neuromodulation therapy market. The expansion of its FDA clearances, along with a proactive stance on operational efficiency, suggests positive prospects for growth in revenue and overall market stability.
Frequently Asked Questions
What is NeurAxis's recent revenue growth?
NeurAxis reported a revenue increase of 22%, totaling $811 thousand for the third quarter of 2025 compared to $667 thousand in the previous year.
What FDA clearances has NeurAxis achieved?
The company received FDA clearance for treating pain related to Functional Dyspepsia and has expanded its indication to include pediatric patients aged 8 to 21 years.
How much cash does NeurAxis have on hand?
As of September 30, 2025, NeurAxis has a cash balance of $4.4 million, strengthened by an additional $2.8 million raised from equity offerings in October.
What are NeurAxis's future plans?
NeurAxis aims to expand its operational reach and increase revenue significantly in 2026 while ensuring that its therapies are more accessible to patients.
How does NeurAxis support uninsured patients?
NeurAxis runs financial assistance programs that help uninsured patients, contributing to increased patient enrollment and sales growth.
